Investors

Press Releases

Press Releases

Date Title View
Toggle Summary Liquidia Announces Special Meeting Date to Approve Proposed Acquisition of RareGen, LLC
Special Meeting of Liquidia Technologies, Inc. Stockholders Scheduled for October 21, 2020 RESEARCH TRIANGLE PARK, N.C. , Sept. 17, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization
View HTML
Toggle Summary Liquidia Announces Notice of Allowance for U.S. Patent Application Covering Methods of Treating Pulmonary Hypertension with Dry Powder Treprostinil
RESEARCH TRIANGLE PARK, N.C. , Aug. 28, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT ®  technology, today announced that it has
View HTML
Toggle Summary Liquidia Announces Chief Financial Officer Transition
Steven Bariahtaris Appointed Interim Chief Financial Officer RESEARCH TRIANGLE PARK, N.C. , Aug. 20, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its
View HTML
Toggle Summary Liquidia Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Received FDA Acceptance of LIQ861 NDA for Review Reported Final Safety and Tolerability Results for LIQ861 INSPIRE Trial Appointed Tushar Shah , M.D. as Chief Medical Officer Announced Definitive Agreement to Acquire RareGen, LLC Completed Public Offering of Common Stock Company to Host Webcast and
View HTML
Toggle Summary Liquidia to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
RESEARCH TRIANGLE PARK, N.C. , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that Neal
View HTML
Toggle Summary Liquidia Releases Exploratory Endpoint Data from INSPIRE Study at the American Thoracic Society (ATS) Annual Meeting
New data from INSPIRE LIQ861 safety and tolerability study in pulmonary arterial hypertension (PAH) patients demonstrate positive trends in exploratory endpoints, including quality of life (QoL) RESEARCH TRIANGLE PARK, N.C. , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc.
View HTML
Toggle Summary Liquidia to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020
RESEARCH TRIANGLE PARK, N.C. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced that second quarter
View HTML
Toggle Summary Liquidia Responds to United Therapeutics Corporation Lawsuit Alleging Infringement of New Tyvaso Patent
RESEARCH TRIANGLE PARK, N.C. , July 24, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that United
View HTML
Toggle Summary Liquidia Announces Closing of Public Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C. , July 02, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT ®  technology, announced the closing of its
View HTML
Toggle Summary Liquidia to Host Conference Call to Provide Update on Recent Announcements
RESEARCH TRIANGLE PARK, N.C. , June 29, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT ®  technology, will host a webcast and
View HTML